Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment with brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma
jRCT1080223715Phase 4Completed
- Sponsor
- Takeda
- Start
- Nov 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (ALCL), sponsored by Takeda. Primary endpoints: Efficacy of brentuximab vedotin retreatment and Safety of brentuximab vedotin retreatment. Started Nov 2017; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)systemic anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on jRCT1080223715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223715.